Europe PMC

Background Psoriasis is a chronic skin disease affecting millions of people, with obesity being a common comorbidity. Many studies suggest that obesity may influence the onset and treatment efficacy of psoriasis. Currently, increasing evidence indicates that abdominal obesity is associated with various metabolic diseases, but research on the relationship between abdominal obesity and psoriasis remains limited. This study uses advanced obesity indicators such as the conicity index and body roundn

Objectives To explore the extent to which skin severity is reflected in the Psoriatic Arthritis Disease Activity Score (PASDAS).Methods Cross-sectional baseline data from the British Society for Rheumatology PsA register (BSR-PsA) and the GRAPPA Composite Exercise (GRACE) dataset was included. The body surface area score (BSA) and the Dermatology Life Quality Index (DLQI) were used to assess skin disease activity. BSA was categorized as none (0%), mild (<3%), moderate (3-10%) and severe (>

Background Asthma (AS) and chronic obstructive pulmonary disease (COPD) are prevalent chronic airway disorders with shared inflammatory pathways. Considering the systemic inflammatory nature of psoriasis, this study utilized the National Health Interview Survey (NHIS) to investigate its potential association with COPD and AS.Methods Data from the 2023 NHIS were analyzed, with participants selected based on specific inclusion criteria. A baseline table was constructed, and multivariate logistic r

Background Psoriasis is a chronic inflammatory skin disorder characterized by elevated levels of proinflammatory cytokines. Mesenchymal stem cells (MSCs) have demonstrated therapeutic potential, yet the specific mechanisms involved are not fully understood.Objective To investigated the effectiveness of extracellular vesicles (EVs) derived from MSCs that were genetically modified to overexpress miR-146a, in a mouse model of psoriasis.Methods To enhance miR-146a expression, MSCs were transfected,

Background Psoriatic arthritis (PsA) and juvenile PsA (jPsA) are chronic inflammatory diseases with similar features that differ by age and sequence of symptom onset. PsA and psoriasis (PsO) share comparable pathology across ages, with interleukin (IL)-23 as a key mediator. Prior to the recent US FDA approval of guselkumab for treatment of pediatric plaque PsO and active jPsA, no approved pediatric treatment selectively targeted IL-23 signaling. Guselkumab (a fully human, dual-acting, IL-23p19 s

Background Psoriasis is a systemic disease that brings enormous mental pressure and economic burden to patients and has a significant impact on patients' quality of life (QoL). This study aimed to explore factors affecting the dermatology life quality index (DLQI) in patients with psoriasis.Methods This retrospective cross-sectional study used data sourced from the Psoriasis Diagnosis and Treatment Real-world Database, and 8839 patients with psoriasis (recruited between June 24, 2020 and Septemb

No abstract supplied.Weiterlesen

Aim: Having psoriasis and being treated with medication could raise concerns regarding family planning and pregnancy (FPP), and no guidelines are available on healthcare practice and information provision regarding FPP for these patients. This study aims to gain insight in the perspectives of patients with psoriasis on this important subject.Methods: A cross-sectional questionnaire study including adult female and male patients with psoriasis, independent of their treatment type.Results: A total

Subclinical inflammation (SI) is clinically relevant in psoriasis (PsO) and psoriatic arthritis (PsA), but quantitative imaging biomarkers are lacking. We evaluated the feasibility of ultrashort echo time (UTE) bicomponent MRI for quantifying Achilles enthesis SI. Conventional MRI showed no group differences, whereas short T2* (T2*s) values were significantly elevated in PsO/PsA compared with healthy volunteers. These findings support the feasibility of UTE bicomponent analysis, as a promising t

Ixekizumab is a monoclonal antibody used in the treatment of moderate-to-severe psoriasis and psoriatic arthritis by targeting interleukin-17 A (IL-17 A). It has demonstrated efficacy in controlling inflammation in autoimmune diseases, though adverse reactions can arise. This case study reports a case of 25-year-old female with psoriatic arthritis undergoing treatment with ixekizumab, who developed acute enlargement and inflammation of a pre-existing sebaceous cyst located posterior to the left

No abstract supplied.Weiterlesen

No abstract supplied.Weiterlesen

Background The pathogenesis of psoriasis is characterized by dysregulated post-translational modifications, with particular emphasis on fucosylation-a glycosylation process mediated by fucosyltransferases (FUTs). Keratin 17 (K17), overexpressed in psoriatic keratinocytes, drives inflammation and proliferation, but its interplay with fucosylation remains unclear. This study aimed to elucidate the role of fucosylation in psoriasis, specifically focusing on the regulation of K17 stability by FUT11.

Psoriasis is an autoimmune skin disease associated with increased incidence and severity of chronic kidney disease and hypertension. The mechanisms linking psoriasis skin inflammation with these comorbidities remain unclear. We used flow cytometry, radiotelemetric blood pressure measurements, and histological and ELISA-based assessments of renal damage in mice with experimental psoriasis induced by keratinocyte-specific overexpression of Tie2 (KC-Tie2) and their littermate controls. Compared wit

Background Investigating gender-specific differences in rheumatology is crucial for improving personalized treatment. The present study aimed to explore gender differences in psychological characteristics and features associated with impaired physical and mental quality of life in male and female patients affected by axial spondyloarthritis or psoriatic arthritis.Methods The present study is cross-sectional. Quality of life was evaluated using a Medical Outcome Study 36-item Short Form health su

Psoriasis, a chronic autoimmune skin disease, arises from both genetic predisposition and environmental factors, including Adverse Childhood Experiences (ACEs). This cross-sectional study investigated the association between ACEs, family history, and early-onset psoriasis (≤ 18 years), with particular attention to gender differences. Among 102 psoriasis patients (54 early-onset, 48 late-onset), the early-onset group demonstrated a higher proportion of females, greater prevalence of parental psor

Pustular psoriasis is a rare and severe variant of psoriasis characterized by the eruption of sterile pustules, which may present in distinct clinical patterns. The pathologic features of psoriasis, including keratinocyte hyperproliferation, neutrophilic infiltration, and immune dysregulation, are markedly accentuated. Generalized pustular psoriasis (GPP) displays clinical heterogeneity in age of onset, severity, and disease course. Several overlapping phenotypes are recognized. A variable relat

Background Psoriasis is a chronic inflammatory disease associated with abnormalities in the immune system. Microsomal prostaglandin E synthase-1 (mPGES-1), a terminal enzyme for prostaglandin (PG) E2 biosynthesis, is highly expressed in the skin of psoriasis patients. However, the detailed role of mPGES-1 in psoriasis remains unclear. In the present study, we aimed to investigate the role of mPGES-1 in psoriasis-like skin inflammation induced by imiquimod (IMQ), a well-established model of psori

No abstract supplied.Weiterlesen

Psoriasis and psoriatic arthritis (PsA) are chronic immune-mediated inflammatory diseases associated with obesity, cardiometabolic disease, and mortality. The glucagon-like peptide-1 (GLP1) pathway has emerged as a key factor in the development of obesity and cardiometabolic disease. GLP1 receptor agonists demonstrably improve insulin resistance, dyslipidemia, obesity, and mortality, with emerging evidence suggesting potential benefit for psoriasis. To evaluate whether GLP1 biology influences ps

Psoriasis is a common chronic immune-mediated inflammatory skin disease that presents significant challenges in clinical management. Gentiopicroside (GPS), a bioactive compound derived from Gentiana scabra, has been reported to possess anti-inflammatory and immunomodulatory properties. However, its potential role in the treatment of psoriasis remains unclear. This study aimed to investigate the therapeutic effects of GPS on psoriasis-like dermatitis and elucidate its underlying mechanisms. A pso

Background Psoriatic arthritis (PsA) is a complex immune-mediated heterogeneous inflammatory disease. Treatment decisions are challenging given the multisystem involvement. To further guide management strategies, we conducted a comparative analysis of the latest global guidelines highlighting the contrast in their approach to treat different PsA domains.Methods Major global guidelines for PsA management were reviewed, including American College of Rheumatology 2018 update, European Alliance of A

Background Placebo effects are a significant challenge in the conduct of clinical trials. We explored how global recruitment patterns influence the extent of placebo responses in randomized controlled trials of psoriatic arthritis and plaque psoriasis.Methods We conducted an analysis of 51 trials (6,843 patients; 52±5.7% female) in psoriatic arthritis, and 43 trials (5,671 patients; 32±7.1% female) in plaque psoriasis investigating biological and targeted synthetic therapeutics. We investigated

Purpose Psoriasis is a chronic, immune-mediated skin disease that significantly affects patients' quality of life. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, has emerged as a promising treatment for moderate to severe psoriasis, offering an alternative to biologics with a favorable safety profile. This study analyzes global research trends, key contributors, and emerging focus areas concerning apremilast in the treatment of psoriasis.Patients and methods Publications related to ap

Psoriasis is a chronic inflammatory skin disease driven by immune dysregulation and often exacerbated by metabolic comorbidities. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type 2 diabetes mellitus (T2DM) and weight management, have emerged as a promising treatment due to their anti-inflammatory and immunomodulatory properties. This review evaluates the clinical efficacy, mechanisms of action, and limitations of GLP-1RAs, such as liraglutide, exenatide, and sem